Nonpeptide Peptidomimetics PPI Library
ChemDiv’s library of small molecule peptidomimetics contains 18,417 compounds.
Peptidomimetics are innovative molecules crafted to address the pharmacokinetic challenges associated with therapeutic proteins and peptides. They are specifically designed to emulate the structure and biological activity of bioactive proteins or peptides while exhibiting improved pharmacokinetic properties. These synthetic analogs are categorized into four distinct classes based on their structure and design approach.
Classes A and B consist of peptidomimetics that resemble peptides, with modifications to the peptide side chains and backbone aimed at enhancing their stability and bioavailability. Despite these alterations, therapeutic applications of peptides often encounter limitations due to poor oral bioavailability and susceptibility to proteolytic degradation, resulting in significantly reduced biological half-lives.
Class C peptidomimetics are characterized by their highly modified structures, wherein the entire peptide backbone is replaced with a small molecule scaffold. This radical redesign not only maintains the spatial arrangement of key side chain functionalities analogous to those in the bioactive peptide but also significantly enhances oral bioavailability and overall pharmacokinetic profiles.
Class D peptidomimetics are small-molecule drugs developed through classical medicinal chemistry approaches to replicate the bioactive peptide's mode of action without directly mimicking its side chain functionalities. These molecules exert their effects by binding to either the active site or an allosteric site of a target protein. They can be derived from the optimization of a Class C peptidomimetic or identified through the screening of compound libraries and in silico virtual library screenings.
Peptidomimetics hold promising potential for multiple applications, particularly in cancer diagnostics and therapeutics. They have been explored in various protein model systems, including apoptosis regulators, transmembrane receptors, small GTPases, and transcriptional regulators, demonstrating their versatility and potential in advancing medical science.
Our library of small molecule compounds acting as peptidomimetics presents a cornerstone in drug discovery, offering unparalleled advantages for the discovery of novel therapeutics. These compounds combine the biological potency and specificity of peptides with the desirable pharmacokinetic properties of small molecules, including enhanced stability, bioavailability, and oral absorption. Their structural diversity and modifiability enable the precise targeting of various biological pathways and receptors, often unreachable by traditional small molecules or biologics. This unique blend of features facilitates the development of highly specific, effective, and safer therapeutic agents, capable of addressing complex diseases with minimized side effects. Moreover, peptidomimetics' versatility accelerates the identification and optimization of lead compounds, significantly reducing the time and cost associated with drug development and paving the way for breakthroughs in treating challenging conditions.